Table 5.
Patients characteristics, clinicopathological features, and RT-PCR analysis: association with OS. Results from Kaplan-Meier univariate and Cox multiple regression analyses performed on the subset of patients with complete data (N = 64).
| Covariates | N | 5-year survival | Kaplan-Meier | Cox regression | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Deaths | SP∗ | |||||||||
| n | % | % | HR | 95% CI | p valuea | HRc | 95% CI | p valued | ||
| Gender | 0.872 | 0.826 | ||||||||
| Female | 15 | 6 | 60.0 | 59.3 | 1 | 1 | ||||
| Male | 49 | 21 | 43.9 | 56.4 | 1.07 | 0.43–2.67 | 0.68 | 0.26–1.78 | ||
| Age at diagnosis | 0.922 | 0.678 | ||||||||
| ≤70 years | 38 | 16 | 42.10 | 57.9 | 1 | 1 | ||||
| >70 years | 26 | 11 | 42.3 | 53.6 | 0.96 | 0.45–2.08 | 0.77 | 0.27–2.19 | ||
| Smoking habit | 0.125 | 0.174 | ||||||||
| Ex/never-smoker | 23 | 7 | 30.4 | 69.0 | 1 | 1 | ||||
| Current smoker | 41 | 21 | 50.0 | 49.3 | 1.97 | 0.83–4.66 | 1.81 | 0.76–4.30 | ||
| Pathological TNM | <0.000b | 0.001 | ||||||||
| Stage I | 37 | 9 | 24.3 | 74.5 | 1 | 1 | ||||
| Stage II | 11 | 7 | 65.6 | 36.4 | 3.49 | 1.30–9.34 | 3.49 | 1.30–9.40 | ||
| Stage III | 16 | 11 | 78.7 | 31.3 | 4.39 | 1.81–10.7 | 4.39 | 1.41–10.68 | ||
| Histological type | 0.519 | 0.777 | ||||||||
| Nonsquamous | 39 | 18 | 46.2 | 52.5 | 1 | 1 | ||||
| Squamous | 25 | 9 | 46.0 | 63.7 | 0.77 | 0.35–1.71 | 0.79 | 0.29–2.11 | ||
| ERCC1 (median mRNA expression level) | 0.574 | 0.619 | ||||||||
| <0.419 | 38 | 15 | 39.5 | 60.4 | 1 | 1 | ||||
| ≥0.419 | 26 | 12 | 47.2 | 52.7 | 1.24 | 0.58–2.66 | 1.14 | 0.38–3.44 | ||
| BRCA1a (median mRNA expression level) | 0.970 | 0.854 | ||||||||
| <0.071 | 36 | 15 | 41.7 | 57.8 | 1 | 1 | ||||
| ≥0.071 | 28 | 12 | 42.9 | 56.7 | 1.02 | 0.47–2.17 | 0.97 | 0.37–2.55 | ||
| TSa (median mRNA expression level) | 0.264 | 0.554 | ||||||||
| <0.179 | 28 | 10 | 35.7 | 63.7 | 1 | 1 | ||||
| ≥0.179 | 36 | 17 | 47.2 | 52.1 | 1.56 | 0.71–3.41 | 1.21 | 0.48–3.08 | ||
| p53R2 (median mRNA expression level) | 0.915 | 0.807 | ||||||||
| <0.054 | 34 | 14 | 42.2 | 58.4 | 1 | 1 | ||||
| <0.054 | 30 | 13 | 42.7 | 55.7 | 1.04 | 0.49–2.28 | 1.07 | 0.39–2.93 | ||
| TUBB3 (median mRNA expression level) | 0.408 | 0.355 | ||||||||
| <0.453 | 33 | 12 | 46.4 | 63.6 | 1 | 1 | ||||
| ≥0.453 | 31 | 15 | 48.4 | 50.2 | 1.38 | 0.65–2.95 | 1.46 | 0.67–3.18 | ||
| RRM1 | 0.255 | 0.293 | ||||||||
| ≤0.128 | 31 | 11 | 45.5 | 64.4 | 1 | 1 | ||||
| >0.128 | 33 | 16 | 49.50 | 50.6 | 1.56 | 0.73–3.37 | 1.63 | 0.75–3.54 | ||
| RRM2 | 0.209 | 0.228 | ||||||||
| <0.275 | 31 | 11 | 45.5 | 64.0 | 1 | 1 | ||||
| ≥0.275 | 33 | 16 | 49.5 | 50.1 | 1.64 | 0.76–3.53 | 1.2 | 0.42–3.46 | ||
∗SP = cumulative probability of surviving, alog-rank (Mantel-Cox) test, btest for trend, cCox regression analysis performed on 64 subjects with complete data: HR and 95% CI estimated from the final regression model for covariates retained in the model and from the full model for variables removed, and dlikelihood ratio test p value.